Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Status: | Recruiting |
---|---|
Conditions: | Neurology, Neurology, Neurology, Neurology, Neurology, ALS |
Therapuetic Areas: | Neurology, Other |
Healthy: | No |
Age Range: | 18 - 85 |
Updated: | 3/17/2019 |
Start Date: | September 2014 |
End Date: | February 2021 |
Contact: | Ping Wang, MA |
Email: | pwang@ucsf.edu |
Phone: | 415-502-7518 |
Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2
Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of
rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes:
frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration
syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is
to build a FTLD clinical research consortium to support the development of FTLD therapies for
new clinical trials. The consortium, referred to as Advancing Research and Treatment for
Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner
with six patient advocacy groups to manage the consortium. Participants will be evaluated at
14 clinical sites throughout North America and a genetics core will genotype all individuals
for FTLD associated genes.
rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes:
frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration
syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is
to build a FTLD clinical research consortium to support the development of FTLD therapies for
new clinical trials. The consortium, referred to as Advancing Research and Treatment for
Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner
with six patient advocacy groups to manage the consortium. Participants will be evaluated at
14 clinical sites throughout North America and a genetics core will genotype all individuals
for FTLD associated genes.
Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of
rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes:
frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration
syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is
to build a FTLD clinical research consortium (FTLD CRC) to support the development of FTLD
therapies for new clinical trials. The FTLD CRC will be headquartered at UCSF and will
partner with six patient advocacy groups to manage the consortium. Patients will be evaluated
at 13 clinical sites throughout North America and a genetics core will genotype all
individuals for FTLD associated genes.
The study will be divided into 2 projects. The first project will be Preparing for Sporadic
FTLD Clinical Trials and the second project will be a Longitudinal Assessment of Familial
FTLD. Self-registration for an online registry will be available for patients and families
with any FTLD syndrome. Eligible participants for research Projects 1 and 2 FTLD will be
invited to a CRC site for clinical evaluations. All enrolled participants in both research
projects will have a site visit consisting of a neurological exam, medical and family
history, cognitive testing, and a blood draw.
Participants in Project 1 who have a diagnosis of Progressive Supranuclear Palsy Syndrome
will have two additional assessments. A lumbar puncture (LP) will be performed for CSF
collection, and an MRI scan of the brain will be done.
Participants in Project 2: Longitudinal Assessment of familial FTLD will return for a
follow-up visit in 12 months; procedures at the follow-up visit will be identical to those at
baseline. Additionally, asymptomatic participants will undergo MRI scans at both visits.
rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes:
frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration
syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is
to build a FTLD clinical research consortium (FTLD CRC) to support the development of FTLD
therapies for new clinical trials. The FTLD CRC will be headquartered at UCSF and will
partner with six patient advocacy groups to manage the consortium. Patients will be evaluated
at 13 clinical sites throughout North America and a genetics core will genotype all
individuals for FTLD associated genes.
The study will be divided into 2 projects. The first project will be Preparing for Sporadic
FTLD Clinical Trials and the second project will be a Longitudinal Assessment of Familial
FTLD. Self-registration for an online registry will be available for patients and families
with any FTLD syndrome. Eligible participants for research Projects 1 and 2 FTLD will be
invited to a CRC site for clinical evaluations. All enrolled participants in both research
projects will have a site visit consisting of a neurological exam, medical and family
history, cognitive testing, and a blood draw.
Participants in Project 1 who have a diagnosis of Progressive Supranuclear Palsy Syndrome
will have two additional assessments. A lumbar puncture (LP) will be performed for CSF
collection, and an MRI scan of the brain will be done.
Participants in Project 2: Longitudinal Assessment of familial FTLD will return for a
follow-up visit in 12 months; procedures at the follow-up visit will be identical to those at
baseline. Additionally, asymptomatic participants will undergo MRI scans at both visits.
1. Inclusion Criteria:Must meet one of the following research diagnostic criteria for a
Frontotemporal lobar degeneration (FTLD) syndrome: behavioral variant frontotemporal
dementia (bvFTD), primary progressive aphasia (PPA), semantic variant primary
progressive aphasia (svPPA), nonfluent variant primary progressive aphasia (nfvPPA),
frontotemporal dementia with amyotrophic lateral sclerosis (FTD/ALS), amyotrophic
lateral sclerosis alone, corticobasal syndrome (CBS), progressive supranuclear palsy
(PSP) or oligosymptomatic PSP (oPSP), or have a strong family history of FTLD
syndromes.
2. Between 18 and 85 (inclusive) years of age.
3. Able to walk (with assistance) at the time of enrollment.
4. Have a reliable study partner who can provide an independent evaluation of
functioning.
5. Speak English or Spanish
6. Have Mini Mental State Exam (MMSE) scores between 15 - 30 (inclusive).
Exclusion Criteria:
1. Known presence of a structural brain lesion (e.g. tumor,cortical infarct) that could
reasonably explain symptoms in a symptomatic participant without a known f-FTLD
causing mutation.
2. Known presence of an Alzheimer's disease causing mutation in PSEN1, PSEN2 or APP; or
neuropathological evidence for Alzheimer's disease as a cause of syndrome (from brain
biopsy).
3. A previous history of Korsakoff encephalopathy, severe alcohol dependence (within 5
years of onset of dementia), frequent alcohol or other substance intoxication, or
other neurological disorder (such as multiple sclerosis)
4. Evidence through history or laboratory testing of B12 deficiency (B12 < 95% of local
laboratory's normal value), hypothyroidism (TSH >150% of normal), HIV positive,renal
failure (creatinine > 2), liver failure (ALT or AST > two times normal), respiratory
failure (requiring oxygen), extra-axial brain tumor (with visible compression of the
brain parenchyma), large cerebral infarct that could account for clinical syndrome,
large confluent white matter lesions (grades 3 or 4, [107] significant systemic
medical illnesses such as deteriorating cardiovascular disease;
5. Current medication likely to affect CNS functions in the opinion of the site PI: long
acting benzodiazepines such as diazepam (short-acting benzodiazepines are OK),
non-SSRI antidepressants (SSRIs or trazodone are OK), no lithium, typical neuroleptics
as listed in the Manual of Procedures, narcotics (codeine is OK, but hold 24 hours
before neuropsychological testing), anticonvulsants (outside of therapeutic ranges),
antihistamines (if taking greater than three times per week; hold 24 hours before
neuropsychological testing).
6. In the site investigator's opinion, the participant cannot complete sufficient key
study procedures, or equivalent assessment of impairment level.
7. For groups where MRI scans are planned procedures, any contraindication for MRI
scanning, such as pacemaker or other implanted metals.
We found this trial at
17
sites
Saint Louis, Missouri 63110
Principal Investigator: Nupur Ghoshal, MD, PhD
Phone: 314-362-3839
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
Baltimore, Maryland 21205
410-516-8000
Principal Investigator: Chiadi U Onyike, MD, MHS
Phone: 410-502-5816
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
Principal Investigator: Yvette Bordelon, MD, PhD
Phone: 310-478-3711
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
Click here to add this to my saved trials
116th St and Broadway
New York, New York 10027
New York, New York 10027
(212) 854-1754
Principal Investigator: Edward D Huey, MD
Phone: 212-305-5710
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
Click here to add this to my saved trials
Birmingham, Alabama 35294
Principal Investigator: Erik Roberson, MD
Phone: 205-996-3659
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Principal Investigator: Daniel Kaufer, MD
Phone: 919-962-8852
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
Click here to add this to my saved trials
Charlestown, Massachusetts 02129
Principal Investigator: Bradford C Dickerson, MD
Phone: 617-726-6205
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Chicago, Illinois 60611
Principal Investigator: Sandra Weintraub, PhD
Phone: 312-503-1925
Click here to add this to my saved trials
11100 Euclid Avenue
Cleveland, Ohio 44106
Cleveland, Ohio 44106
Principal Investigator: Brian Appleby, MD
Phone: 216-464-6203
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
Dallas, Texas 75390
(214) 645-3300
Principal Investigator: Diana Kerwin, MD
Phone: 214-648-8543
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
Click here to add this to my saved trials
Jacksonville, Florida 32216
Principal Investigator: Neill Graff-Radford, M.D.
Phone: 904-953-9680
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Murray Grossman, M.D.
Phone: 215-349-5873
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
Rochester, Minnesota 55905
507-284-2511
Principal Investigator: Bradley F Boeve, M.D.
Phone: 507-538-9487
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
San Diego, California 92093
Principal Investigator: Irene Litvan, MD
Phone: 858-822-5786
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Adam Boxer, MD, PhD
Phone: 415-502-7518
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Kimiko Domoto-Reilly, MD
Phone: 206-221-9038
Click here to add this to my saved trials
Vancouver, British Columbia V6T 1W5
Principal Investigator: Robin Hsiung, MD
Phone: 604-822-7989
Click here to add this to my saved trials